Dupilumab treatment of atopic dermatitis leading to successful treatment of alopecia universalis: A Japanese case report

Muto, Jun; Yoshida, Shigetoshi; Doi, Chiaki; Habu, Minako; Sayama, Koji

doi:10.1111/1346-8138.15631

Cited by 6 publications

(6 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Renert-Yuval et al [131] provided an overview of activated immune pathways in alopecia areata, in which they analyzed overexpression of IL-4 and IL-13 and possible therapeutic modalities, including dupilumab. Recently, cases of alopecia areata [132][133][134][135][136][137][138][139][140] and alopecia universalis [135,[140][141][142][143][144][145][146][147] have been reported to heal during treatment with dupilumab for AD. Therefore, this dual efficacy of dupilumab for AD and alopecia areata/alopecia universalis may be explained by their shared immunopathogenic mechanisms.…”

Section: Alopecia Areatamentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

Recent advances in understanding T2 inflammation have broadened the diseases in which T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody blocking the signaling of both IL-4 and IL13, two crucial cytokines of the T2 responses. New possible indications are increasingly exploring. Among them are skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, among other several cutaneous diseases. Also, respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy are two more research fields. Here we review the published data and clinical trials about the use of dupilumab in these disorders.

show abstract

Section: Alopecia Areatamentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

show abstract

“…One case of incontinentia pigmenti-associated scalp alopecia was reported. Clinical responses were mostly measured by the severity of alopecia tool (SALT) with a score < 10 defined as complete response ( Table 4 ) [ 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 ]. Noticeably, 13 pediatric patients were treated effectively with dupilumab [ 172 , 173 , 174 , 175 , 176 , 177 ].…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

“…Indeed, contradicting information has been published about AA in dupilumab‐treated patients with AD. While some studies have reported the development of AA as an AE to dupilumab, others showed the healing of AA in patients affected by the two diseases 33–51 . Furthermore, dupilumab has been studied for the treatment of AA, but the results of phase 2 randomized clinical trials are scant 52 .…”

Section: Discussionmentioning

confidence: 99%

Dupilumab‐associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study

Napolitano

Fabbrocini

Patruno

2023

The Journal of Dermatology

View full text Add to dashboard Cite

Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL‐13, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged ≥6 years, adolescents, and adults. Both clinical trials and real‐life data demonstrate its efficacy and safety. However, some cutaneous adverse events (cAEs) have been observed during real‐world experiences. The authors’ aim was to analyze the spectrum of cAEs in patients receiving dupilumab for the treatment of AD in a real‐world setting. A retrospective review of electronic medical records was conducted for 916 patients (475 males and 541 females; mean age, 50.23 ± 19.66 years [range, 18–91 years]) who had received dupilumab for a minimum of 1 month for the treatment of AD from December 2018 to November 2022 at the Department of Dermatology of University Federico II of Naples (Italy). The mean duration of dupilumab treatment was 27.31 ± 21.26 months. A total of 148 of 916 (16.15%) (90 males; mean age, 50.91 ± 15.34 years) patients reported other cAEs apart of AD flare; namely, facial redness (82 of 916; 8.95%), psoriasis (39 of 916; 4.25%), alopecia areata (11 of 916; 1.2%), skin peeling (11 of 916; 1.2%), parapsoriasis (three of 916; 0.32%), and vitiligo (two of 916; 0.21%). Thirty‐one of 916 (3.38%) patients discontinued dupilumab because of cAEs (18 of 916; 1.96%) for facial redness, 10 of 916 (1.09%) for psoriasis, and three of 916 (0.32%) for parapsoriasis. In our population, most of the cAEs were mild and did not require discontinuation of dupilumab. These findings would enable dermatologists understand the cutaneous side effects of dupilumab better, resulting in improved treatment plan decisions in clinical practice.

show abstract

Dupilumab treatment of atopic dermatitis leading to successful treatment of alopecia universalis: A Japanese case report

Cited by 6 publications

References 5 publications

Dupilumab: A Review of Present Indications and Off-Label Uses

Dupilumab: A Review of Present Indications and Off-Label Uses

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab‐associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study

Contact Info

Product

Resources

About